Protocol for the neonatal intracerebroventricular delivery of adeno-associated viral vectors for brain restoration of MECP2 for Rett syndrome
Brief intro:
- Author: Kan Yang, Tianshu Li, Yixiao Geng, Ru Zhang, Zhankui Xu, Jun Wu, Yiting Yuan, Yuefang Zhang, Zilong Qiu, Fei Li
- Journal: STAR Protocols
- Doi: https://www.doi.org/10.1016/j.xpro.2024.103344
- Publication Date: 2024 Dec 20
Products/Services used in the paper
Quotation shows PackGene:AAV9-Vector (AAV9-CAG-Vector-GFP) PackGene Biotech.
Research Field:Rett syndrome
AAV Serotype:AAV9
Targeted organ:brain
Animal or cell line strain:mice
Abstract
Highlights: •Instructions for the intracerebroventricular delivery of AAV in neonatal mice; •Steps to determine neonate genotype using PCR combined with agarose gel electrophoresis; •Steps to prepare foster mothers to decrease infanticide; •Safe and effective steps for pups from awake state to anesthesia induced by hypothermia;
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
